Gilead Sciences
Why trials sponsored by Gilead Sciences stopped, in this sample of ClinicalTrials.gov.
23 stopped trials with a clear reason; 70% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 11 | 48% |
| futility | 5 | 22% |
| slow accrual | 3 | 13% |
| safety | 2 | 9% |
| logistics pi | 1 | 4% |
| regulatory | 1 | 4% |
Where it ranks
- #3 of 90 sponsors by share of trials stopped for: futility (22%).
Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.
Trials
- Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
NCT06784973 · TERMINATED · funding business
“Study was terminated by Sponsor; the decision was not due to any safety findings.” - Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
NCT06613685 · TERMINATED · funding business
“Sponsor decision to terminate study.” - Study of GS-0272 in Participants With Rheumatoid Arthritis
NCT06031415 · TERMINATED · futility
“Study terminated due to lack of efficacy.” - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
NCT05006794 · TERMINATED · funding business
“Sponsor decision to terminate” - Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
NCT04745351 · TERMINATED · funding business
“The study was terminated due to study enrollment feasibility. This decision is not based on efficacy or safety concerns.” - Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
NCT04747470 · TERMINATED · funding business
“Sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule, GS-3583.” - Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
NCT04483687 · WITHDRAWN · funding business
“Development program terminated” - Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
NCT04501952 · TERMINATED · funding business
“The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.” - Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
NCT04115839 · TERMINATED · funding business
“Development program terminated” - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
NCT04060147 · TERMINATED · slow accrual
“The study enrollment was terminated early by the sponsor due to recruitment challenges.” - Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
NCT03701438 · TERMINATED · regulatory
“The Swissmedic agency released Gilead from this post marketing requirement.” - Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
NCT03434353 · TERMINATED · funding business
“Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.” - Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
NCT03219164 · TERMINATED · logistics pi
“Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.” - Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT03053063 · TERMINATED · futility
“This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.” - Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
NCT02842086 · TERMINATED · safety
“Following review of accumulated safety data from DISCOVER and real-world use of F/TAF, the sponsor determined that the long-term safety of F/TAF had been demonstrated and no further safety monitoring within the study was required.” - Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
NCT02457598 · TERMINATED · futility
“The goal of the study was to improve tolerability while maintaining or increasing efficacy. The results of this study showed no efficacy advantage although the combinations were well tolerated.” - Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
NCT01799889 · TERMINATED · funding business
“Sponsor's decision to discontinue development of entospletinib.” - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
NCT01101581 · WITHDRAWN · slow accrual
“No subjects enrolled” - Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
NCT00650949 · TERMINATED · funding business
“Strategic” - Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection
NCT00874796 · TERMINATED · safety
“Reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.” - DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
NCT00389675 · TERMINATED · futility
“Study DAR-312 did not meet its primary co-endpoints.” - DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
NCT00353574 · TERMINATED · futility
“Study DAR-312 did not meet primary co-endpoints” - Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
NCT00113802 · TERMINATED · slow accrual
“low accrual”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.